DE vs DHR: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
Deere & Company · Industrials
$596.74
-29.8% upside to fair value
Grade C
High Quality
VS
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
DE trades at a lower forward P/E
(33.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
DHR |
| Current Price |
$596.74 |
$195.98 |
| Fair Value Estimate |
$418.72 |
$211.54 |
| Upside to Fair Value |
-29.8%
|
+7.9%
|
| Market Cap |
$161.1B |
$138.7B |
| Forward P/E |
33.7x
|
37.8x
|
| EV / EBITDA |
19.0x
|
22.8x
|
| Price / Sales |
3.4x
|
5.6x
|
| Price / FCF |
42.8x
|
26.2x
|
| Revenue Growth YoY |
+6.7%
|
+3.7%
|
| Gross Margin |
35.4%
|
60.7%
|
| Operating Margin |
18.4%
|
21.0%
|
| Return on Equity |
18.3%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.34%
|
3.81%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Deere & Company operates in the agricultural machinery sector, providing durable equipment critical to farming and construction industries. The business quality is high, supported by a strong 18.3% return on equity and solid gross and operating margins of 35.4% and 18.4%, respectively. However, the stock is currently overvalued, trading approximately 30% above its fair value estimate of $418.72, …
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Accumulation Zones
| Metric |
DE |
DHR |
| Zone Low |
$314.04 |
$158.66 |
| Zone High |
$355.91 |
$179.81 |
| In Buy Zone? |
No
|
No
|